OphthalmologyNews.net

Ophthalmology Xagena

Xagena Mappa
Medical Meeting
Xagena Salute
Onco News

Golimumab could be an effective and safe therapy for the management of patients with uveitis previously treated with other anti-TNF-alpha drugs


The aim of a study was to assess the clinical response to Golimumab ( Simponi ) in patients with non-infectious uveitis from a single centre that had previously been treated with other anti-TNF-alpha drugs.

A retrospective chart review was carried out of patients with immune-mediated uveitis refractory to standard synthetic immunosuppressive drugs who were treated with Golimumab at Hospital Universitario Marqués de Valdecilla, Santander ( Spain ).
Patients were included in this study if they had previously been treated with other anti-TNF-alpha therapy.

A literature review of patients with immune-mediated uveitis undergoing Golimumab therapy was conducted.

Three patients ( 2 men and 1 woman ) were included in this study. Two of them were refractory to other anti-TNF-alpha drugs. The median age of patients was 26 years ( range 20-42 ).
Uveitis was bilateral in two patients. The underlying diseases were uveitis associated with HLA-B27 and psoriasis in one case and sarcoidosis in the other two cases.

Improvement of the main ocular parameters following Golimumab therapy was achieved in all cases.

After a median follow-up of 3 ( range 1-9 ) months using Golimumab therapy, none of the patients had experienced new relapses of uveitis.

None of them had side effects during treatment with this drug.

A literature review disclosed that the observations were in keeping with other reports that showed good response to Golimumab in 13 of 16 patients with immune-mediated uveitis refractory to other biologic agents.

In conclusion, although the follow-up was too short in the series, Golimumab could be an effective and safe therapy for the management of patients with uveitis previously treated with other anti-TNF-alpha drugs. ( Xagena )

Calvo-Río V et al, Clin Exp Rheumatol 2014; Epub ahead of print

XagenaMedicine_2014



Indietro